|
|
|
|
| LEADER |
01000cam a22002652 4500 |
| 001 |
823590674 |
| 003 |
DE-627 |
| 005 |
20230905071648.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
150429s2015 xxu|||||o 00| ||eng c |
| 020 |
|
|
|a 9781118268063
|9 978-1-118-26806-3
|
| 020 |
|
|
|a 1119006112
|9 1-119-00611-2
|
| 020 |
|
|
|a 1119006031
|9 1-119-00603-1
|
| 020 |
|
|
|a 1118268067
|c cloth
|9 1-118-26806-7
|
| 020 |
|
|
|a 1119006236
|c : ePub
|9 1-119-00623-6
|
| 020 |
|
|
|a 9781119006114
|9 978-1-119-00611-4
|
| 020 |
|
|
|a 9781119006039
|9 978-1-119-00603-9
|
| 020 |
|
|
|a 9781118268063
|c : cloth
|9 978-1-118-26806-3
|
| 020 |
|
|
|a 9781119006237
|c : ePub
|9 978-1-119-00623-7
|
| 035 |
|
|
|a (DE-627)823590674
|
| 035 |
|
|
|a (DE-599)GBV823590674
|
| 035 |
|
|
|a (EbpS)985082
|
| 040 |
|
|
|a DE-627
|b eng
|c DE-627
|e rda
|
| 041 |
|
|
|a eng
|
| 044 |
|
|
|c XD-US
|
| 050 |
|
0 |
|a RS164
|
| 060 |
|
0 |
|a WB 925
|
| 072 |
|
7 |
|a MED 071000
|2 bisacsh
|
| 100 |
1 |
|
|a Ramzan, Iqbal
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Phytotherapies
|b Efficacy, Safety, and Regulation
|
| 264 |
|
1 |
|a Hoboken
|b Wiley
|c 2015
|
| 300 |
|
|
|a Online-Ressource (683 p)
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a Computermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Description based upon print version of record
|
| 505 |
8 |
0 |
|a Title Page; Copyright Page; Contents; List of Contributors; Preface; Chapter 1 Phytotherapies-Past, Present, and Future; 1.1 Overview of Phytotherapy; 1.1.1 Definition; 1.1.2 International Trend in the Usage of Complementary Medicines; 1.2 Preclinical Research on Phytotherapies; 1.2.1 Pharmacognosy and Quality Standardization of Phytotherapies; 1.2.2 Pharmacological Studies and Identification of Bioactive Compounds; 1.2.3 Application of Proteomics and Metabolomics in Phytotherapy Research; 1.3 Clinical Research on Phytotherapies; 1.3.1 Efficacy of Popular Phytotherapies
|
| 505 |
8 |
0 |
|a 1.3.2 Chinese Herbal Medicines1.3.3 Food Nutrition and Translational Research; 1.4 Safety of Phytotherapies; 1.5 Profile of Research in Complementary Medicine; 1.5.1 International Profile; 1.5.2 Australian Profile of Research in Complementary Medicines; 1.6 Summary and Future Directions; References; Chapter 2 Quality Control and Quality Assurance of Phytomedicines: Key Considerations, Methods, and Analytical Challenges; 2.1 Introduction; 2.2 Key Considerations in QC/QA of Phytomedicines; 2.2.1 Identification and Good Agricultural and Collection Practices (GACP); 2.2.2 Contamination
|
| 505 |
8 |
0 |
|a 2.2.3 Substitution2.2.4 Adulteration; 2.2.5 Contents and Standardization; 2.2.6 Stability; 2.2.7 Processing; 2.3 Methods for QC/QA of Phytomedicines; 2.3.1 Macroscopic Evaluation; 2.3.2 Microscopic Evaluation; 2.3.3 Physicochemical Analysis; 2.3.4 Chemical Fingerprinting; 2.3.5 DNA Fingerprinting; 2.3.6 "Omics" Technology; 2.4 Challenges; 2.5 Conclusions; References; Chapter 3 Preclinical (In Vivo) and Laboratory (In Vitro) Evidence of Phytomedicine Efficacy; 3.1 Introduction to Development of Drugs from Nature; 3.2 Use of In Vitro and In Vivo Models in Herb Drug Research: Learning Thus Far
|
| 505 |
8 |
0 |
|a 3.2.1 In Vitro Assays3.2.2 In Vivo Assays; 3.3 Cardiovascular-and Stroke-Related Diseases: In Vitro and In Vivo Focus; 3.3.1 Cardiovascular Diseases; 3.3.2 Stroke; 3.4 Conclusions; References; Chapter 4 Clinical Efficacy Trials with Natural Products and Herbal Medicines; 4.1 Introduction; 4.2 Trials in Various Disease States; 4.2.1 Profile: RCT of Natural Product in Rheumatoid Arthritis (RA); 4.2.2 Asthma; 4.2.3 Cancer; 4.2.4 Cardiovascular Disease; 4.2.5 Diabetes; 4.2.6 Dermatology; 4.2.7 Gastroenterology; 4.2.8 Viral Infections; 4.3 Natural Product: Green Tea
|
| 505 |
8 |
0 |
|a 4.3.1 Green Tea Catechin, Epigallocatechin Gallate (EGCG)4.4 EGCG Clinical Trials; 4.4.1 Polyphenon E; 4.4.2 Safety, Toxicity, and Pharmacokinetics; 4.4.3 Metabolism; 4.4.4 Clinical Studies; 4.4.5 Cancer Studies; 4.5 Human Clinical Study: EGCG and HIV-1 Infection; 4.5.1 Translational Medicine: EGCG: Bench-to-Bedside; 4.5.2 Phase I Clinical Trial: Polyphenon E in HIV-1 Infection; 4.6 Conclusion; References; Chapter 5 Novel Formulations and Drug Delivery Systems for Phytotherapies; 5.1 Limitations of Conventional Formulations for Herbal Medicines
|
| 505 |
8 |
0 |
|a 5.1.1 Barriers in Physicochemical and Biological Properties
|
| 505 |
8 |
0 |
|t Phytotherapies : past, present, and future
|r Iqbal Ramzan, George Q. LiQuality control and quality assurance of phytomedicines : key considerations, methods, and analytical challenges / Wai-Ping Yau, Cheong Hian Goh, Hwee-Ling Koh
|
| 505 |
8 |
0 |
|t Pre-clinical (in vivo) and laboratory (in vitro) evidence of phytomedicine efficacy
|r Mohi Iqbal Mohammed Abdul, Tom Hsun-Wei Huang
|
| 505 |
8 |
0 |
|t Clinical efficacy trials with herbal medicines
|r Christina L. Nance
|
| 505 |
8 |
0 |
|t Novel formulations and drug delivery systems for phytotherapies
|r Shengpeng Wang, Meiwan Chen, Qi (Tony) Zhou, Hak-Kim Chan
|
| 505 |
8 |
0 |
|t Phytotherapies used by indigenous populations
|r Bradley S. Simpson, Susan J. Semple
|
| 505 |
8 |
0 |
|t Phytotherapies from traditional Chinese medicines
|r Michael Rieder
|
| 505 |
8 |
0 |
|t Integrating traditional Greco-Arab and Islamic herbal medicine in research and clinical practice
|r Bashar Saad
|
| 505 |
8 |
0 |
|t Evolution of herbal medicine in Europe and its relationship with modern medicine
|r Elizabeth M Williamson, Kelvin Chan
|
| 505 |
8 |
0 |
|t Chemical classification and chemistry of phytotherapeutic constituents
|r Pei H. Cui, Colin C. Duke
|
| 505 |
8 |
0 |
|t Therapeutic potential of ginsenosides in management of atherosclerosis
|r Xiao-Jing Zhang, Huanxing Su, Jian-Bo Wan, Yi-Tao Wang
|
| 505 |
8 |
0 |
|t Phytotherapy pharmacophores for major cellular drug targets
|r Jennifer A. Ong, Paul W. Groundwater, David E. Hibbs
|
| 505 |
8 |
0 |
|t Use of kava as a phytotherapeutic agent and kava related hepatotoxicity
|r Dong Fu, Iqbal Ramzan
|
| 505 |
8 |
0 |
|t Phytotherapies as new drug sources : gossypol and curcumin
|r Vivian Wan Yu Liao, Rajeshwar Narlawar, David E. Hibbs, Paul W. Groundwater
|
| 505 |
8 |
0 |
|t Phytotherapies for the management of obesity and diabetes
|r Michel Rapinski, Alain Cuerrier
|
| 505 |
8 |
0 |
|t Phytotherapeutics for cancer therapy
|r Daniel M.-Y. Sze, Hao Liu, Maureen V. Boost, Raimond Wong, Stephen Sagar
|
| 505 |
8 |
0 |
|t Phytomedicines for fatty liver disease and functional gastrointestinal conditions
|r George Q. Li, Moon-Sun Kim, Fangming Jin, Jun-Lae Cho
|
| 505 |
8 |
0 |
|t Phytomedicines for inflammatory conditions
|r Sigrun Chrubasik
|
| 505 |
8 |
0 |
|t Phytotherapies for infectious diseases : are these really useful?
|r Gail B. Mahady, Gabrielle Escalante, Pooja Mikkilineni, Laura J. Mahady, Temitope O. Lawal, Bolanle A. Adeniyi
|
| 505 |
8 |
0 |
|t Phytomedicines for CNS disorders : safe issues for use with anti-epileptic drugs?
|r Sophia Yui Kau Fong, Rosina Yau Mok, Qiong Gao, Yin Cheong Wong, Zhong Zuo
|
| 505 |
8 |
0 |
|t Phytotherapy drug interactions in cancer
|r Andrew J. McLachlan, Stephen J. Clarke
|
| 505 |
8 |
0 |
|t Quality use of medicines (QUM) considerations in phytotherapy
|r Lynn Weekes
|
| 505 |
8 |
0 |
|t Intellectual property and patent issues with phytotherapy products
|r Gint Silin, Jennifer Tan, Kelvin Chan
|
| 505 |
8 |
0 |
|t International regulatory status of phytotherapies
|r Ernest V. Linek.
|
| 520 |
|
|
|a Variously defined by its practitioners, phytotherapies include herbal therapies, treatments used by indigenous peoples around the world, and alternative medicines to classical western drugs. Despite an increasing trend toward the use of phytotherapies for chemoprevention and management of disease in healthcare, the published work about their efficacy and safety is scattered - and scientists need to understand these key issues along with regulatory aspects of phytotherpeutic agents. A number of herbs are likely to cause adverse effects if not properly standardized in clinical trials. Covering
|
| 533 |
|
|
|a Online-Ausg.
|
| 650 |
|
2 |
|a Quality Assurance, Health Care
|
| 655 |
|
0 |
|a Electronic books
|
| 776 |
1 |
|
|z 9781119006114
|c : 243.75 (NL)
|
| 776 |
0 |
8 |
|i Print version
|a Phytotherapies
|d Efficacy, Safety, and Regulation
|
| 856 |
4 |
0 |
|u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=985082
|x Verlag
|3 Volltext
|
| 856 |
4 |
0 |
|u http://onlinelibrary.wiley.com/book/10.1002/9781119006039
|x Verlag
|3 Volltext
|
| 912 |
|
|
|a H-ZDB-35-UBC
|
| 912 |
|
|
|a H-ZDB-35-WIC
|
| 912 |
|
|
|a H-ZDB-4-NLEBK
|
| 912 |
|
|
|a GBV_ILN_20
|
| 912 |
|
|
|a ISIL_DE-84
|
| 912 |
|
|
|a SYSFLAG_1
|
| 912 |
|
|
|a GBV_KXP
|
| 912 |
|
|
|a SSG-OLC-PHA
|
| 912 |
|
|
|a SSG-OPC-PHA
|
| 912 |
|
|
|a SSG-OPC-DE-84
|
| 935 |
|
|
|h GBV
|i hybr
|
| 951 |
|
|
|a BO
|
| 953 |
|
|
|2 045F
|a 615.321
|
| 980 |
|
|
|2 20
|1 01
|x 0084
|b 1572514604
|h ACQ
|k Vervielfältigungen (z.B. Kopien, Downloads) sind nur von einzelnen Kapiteln oder Seiten und nur zum eigenen wissenschaftlichen Gebrauch erlaubt. Keine Weitergabe an Dritte. Kein systematisches Downloaden durch Robots.
|y z
|z 23-10-15
|
| 981 |
|
|
|2 20
|1 01
|x 0084
|r http://onlinelibrary.wiley.com/book/10.1002/9781119006039
|
| 995 |
|
|
|2 20
|1 01
|x 0084
|a ACQ
|
